C-MGDDImmorta Bio
senescent cells, stem cells, personalized therapeutics
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-MGDD
C-MGDDC-MGDDsenescent cells, stem cells, personalized therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Immorta Bio senescent cells, stem cells, personalized therapeutics
Immorta Bio presents its mission as reversing aging, eliminating cancer, and rejuvenating organs. Its named technologies include SenoVax, described as an autologous approach to eliminate senescent cells, and StemCellRevivify, described as rebuilding damaged organs and tissues with stem cells. The site also references an AI-enabled personalized therapeutic paradigm for restoring youthful biology.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Immorta Bio — Early mechanism · Lower middle. Derived deterministically from 6 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical).…
Source: Deterministic